NOV 5
2018
NewsYuhan signs $1.25b licensing deal with Janssen
South Korean pharmaceutical giant Yuhan announced Monday that it had licensed out its new clinical-stage lung cancer drug to Janssen Biotech in a deal potentially valued at up to $1.25 billion
